Immunocore Holdings plc IMCR
29.94 USD -0.54 (-1.76%)
Regular-session close
29.94 0.00 0.00%
After hours · Nov 13, 4:00 PM ET
29.76 Day range 31.00
27.50 52-week range 40.72
- YTD
- -13.74%
- 1 year
- -15.35%
News
benzinga.com Morgan Stanley Maintains Equal-Weight on Immunocore Holdings, Lowers Price Target to $42 Morgan Stanley analyst Sean Laaman maintains Immunocore Holdings (NASDAQ:IMCR) with a Equal-Weight and lowers the price target from $43 to $42.
benzinga.com HC Wainwright & Co. Maintains Buy on Immunocore Holdings, Lowers Price Target to $80 HC Wainwright & Co. analyst Patrick R. Trucchio maintains Immunocore Holdings (NASDAQ:IMCR) with a Buy and lowers the price target from $100 to $80.
globenewswire.com Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 09 November 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company…benzinga.com Immunocore Holdings Announces Data Form Its Phase 1/2 Study Of Brenetafusp Shows 29% Overall Response Rate, 71% Disease Control Rate Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve
benzinga.com Immunocore Hldgs Q3 EPS $(0.28) Misses $(0.10) Estimate, Sales $102.222M Miss $113.438M Estimate Immunocore Hldgs (NASDAQ:IMCR) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.10) by 180 percent. The company reported quarterly sales of $102.222…
benzinga.com Immunocore To Present Phase 1/2 Trial Data Evaluating Brenetafusp Alone And In Combination With KIMMTRAK In HLA-A*02:01-Positive Patients With Metastatic Uveal Melanoma, At 2026 SITC Annual Meeting Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meetingClinical data for…
benzinga.com HC Wainwright & Co. Reiterates Buy on Immunocore Holdings, Maintains $100 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Immunocore Holdings (NASDAQ:IMCR) with a Buy and maintains $100 price target.
